| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Denali Therapeutics Inc. | DNL758 (SAR443122) | Cutaneous lupus erythematosus | Phase 2 | Trial Completed | oral | Immunology |
| Denali Therapeutics Inc. | BIIB122 (DNL151) - (LIGHTHOUSE) | Parkinson's Disease Associated with LRRK2 Pathogenic Mutations | Phase 3 | Oral | Neurology | |
| Denali Therapeutics Inc. | DNL788 (SAR443820) - (HIMALAYA) | Amyotrophic lateral sclerosis (ALS) | Phase 2 | Oral | Neurology | |
| Denali Therapeutics Inc. | DNL343 - (HEALEY) | Amyotrophic lateral sclerosis (ALS) | Phase 2/3 | Data Released | oral | Neurology |
| Denali Therapeutics Inc. | Eclitasertib (DNL758/SAR443122) | Ulcerative colitis (UC) | Phase 3 | Ongoing | Oral | Gastroenterology |
| Denali Therapeutics Inc. | Tividenofusp alfa (DNL310) - (COMPASS) | Hunter syndrome MPS II | PDUFA priority review | Ongoing | Intravenous | Genetic Disorder |
| Dermata Therapeutics Inc. | Xyngari(TM) (DMT310) | Rosacea | Phase 2 | Topical | N/A | |
| Dermata Therapeutics Inc. | DMT410 | Axillary Hyperhidrosis | Phase 2a | Trial Planned | Intralesional | N/A |